Application of radiomics in molecular imaging (18F-FDG-PET/CT) for diagnosis and follow-up of cardiovascular device infections: PREDICT study

2025-524624-21-00 · tracked via the Priya Life Science EU tracker

Sponsor

Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer

Sponsor type

Laboratory/Research/Testing facility

Therapeutic area

Virus Diseases

Decision date

07/04/2026

Enrollment target

200

Sites

Spain

Condition studied

Cardiovascular device infections

Investigational medicinal product(s)

Fludesoxiglucosa (18F)-Curium 185 MBq/mlsolución inyectable

Eligibility

Age group

18-64 years, 65+ years

Sex

Female, Male

Primary endpoint

Diagnostic accuracy of radiomics applied to FDG-PET for CVDIs, compared with conventional visual and semiquantitative interpretation.

Endpoint detail

Performance of AI-based predictive models (combining radiomic and clinical features) for: o Distinguishing infection vs. non-infection. o Predicting resolution of infection and supporting discontinuation of suppressive antimicrobial therapy., Characterization of physiological 18F-FDG uptake patterns in cardiovascular device carriers without infection, stratified by sex and time since implantation.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524624-21-00 on CTIS ↗ ← All trials in the EU